HIV AND ANTIRETROVIRALS: A DISPENSERS PERSPECTIVE WITH A FOCUS ON DRUG INTERACTIONS DR. M.M. PEZA MBCHB (UCT) PG DIPLOMA (HEALTH ECONOMICS) (UCT)

Size: px
Start display at page:

Download "HIV AND ANTIRETROVIRALS: A DISPENSERS PERSPECTIVE WITH A FOCUS ON DRUG INTERACTIONS DR. M.M. PEZA MBCHB (UCT) PG DIPLOMA (HEALTH ECONOMICS) (UCT)"

Transcription

1 HIV AND ANTIRETROVIRALS: A DISPENSERS PERSPECTIVE WITH A FOCUS ON DRUG INTERACTIONS DR. M.M. PEZA MBCHB (UCT) PG DIPLOMA (HEALTH ECONOMICS) (UCT) 2/21/2014

2 HIV STATISTICS IN SOUTH AFRICA One in every 10 South Africans is HIV-positive, according to Statistics South Africa 2013 mid-year population estimate. Other interesting statistics about the SA population: The total number of South Africans living with HIV is about 5.26 million. In the age group 15 49, the HIV prevalence is 15.9%. Stats SA estimates that people will die from Aids-related complications in The total number of people living with HIV has gone up by more than a million from 4 million in 2002, to more than five million in The life expectancy of South Africans has increased by a year to 59.6 (57.7 for males and 61.4 years for females. The province with the lowest life expectancy is the Free State. Over 1.9 million adults and children are receiving antiretroviral treatment nationwide. In May 2012, the government said it had cut the mother-to-child transmission rate from 3.5% in 2010 to less than 2%. (Source: Statistics South Africa 2

3 HIV REPLICATION CYCLE Fusion inhibitors Integrase inhibitors (in development) 1 RNA 2 DNA 3 HIV proteins HIV CD4+ cell 4 5 Reverse transcriptase inhibitors Protease inhibitors

4 DISEASE PROGRESSION OF HIV INFECTED PATIENT SEROCONVERSION AIDS 4

5 WHEN TO START TREATMENT All pregnant women Any child with the virus Adult with AIDS defining condition (TB & CCM) Any Medical Scheme member with CD4 < 350 DOH < 250 Patient MUST want to start ARV s 5

6 THE SAD REALITY 6

7 SA Treatment Guidelines: First Line Therapy 1 NNRTI 2 NRTI Efavirenz OR OR AND OR Nevirapine OR Abacavir FIXED DOSE COMBINATIONS 7

8 GOALS OF ANTI-RETROVIRAL THERAPY (ART) Improve quality of life Reduce HIV-related morbidity and mortality Provide maximal and durable suppression of viral load Restore and/or preserve immune function. 8

9 HOW TO ACHIEVE GOALS OF ART MAXIMAL TREATMENT ADHERANCE COMPLETE SUPRESSION OF VIRAL REPLICATION ACHIEVE GOALS OF ART 9

10 FACTORS LEADING TO ADHERANCE DIFFICULTIES Patient and Doctors perspective on adherence difficulties Doctors Patients(1599 patients) Number of tablets 56% Number of daily intakes 32% Tablet size 51% 33% Side-effects 46% 54% Need to take medication while fasting 19% 42% Need to take medication with food 11% 14% Need for long-life treatment 6% 57% Integration of ART in everyday life 5% 27% 68% 72% 10

11 A SOLUTION: FIXED DOSE COMBINATIONS (FDC) Decrease tablet burden thus improving adherence levels Improved efficacy Fewer side effects Decreased cost Decreased risk of incorrect dosing as patient only takes one tablet once a day Decreased risk of patients defaulting a single tablet to avoid certain side effects (e.g. avoiding Efavirenz to avoid central nervous system side effects) Regimen and stock management simplification The benefits of ART in the form of a FDC results in maximal treatment adherence levels and thus HIV viral suppression 11

12 An Introduction To Drug Interactions Definition: When the effects of one drug are altered by the effects of another drug Precipitant drug: precipitates an interaction Object drug: drug whose action is affected by the precipitant drug Drug interactions can either increase or decrease the effect of the object drug Example of increased effect: Amiodorone (Precipitant) inhibits a cytochrome P 450 isoenzyme CYP2C9 Reduced metabolism of warfarin (Object) Result: Increased anti-coagulant effect 12

13 Drugs likely to be involved in drug interactions: Precipitants It is possible to predict the type of drugs that will be involved in important reactions Drugs likely to cause (precipitant) drug interactions drugs that are highly protein-bound therefore displacing object drugs from protein-binding sites E.g. : Aspirin and sulphonamides, Sodium Valproate Drugs that alter (stimulate/inhibit) the metabolism of other drugs Stimulate:Anticolvulsants, rifampicin, griseofulvin, St John s wort Inhibit: allopurinol, cimetidine, erythromycin, metronidazole monoamine oxidase inhibitors, quinolone antibiotics (e.g. ciprofloxacin) Drugs that affects renal function and alter renal clearance E.g. diuretics 13

14 Drugs likely to be objects of drug interactions It is possible to predict the type of drugs that will be affected by the effects of other drugs Drugs for which a small change in dose can result in a relatively large change in therapeutic effect Change in therapeutic effect Reduced efficacy Low toxic: therapeutic ratio Examples of such drugs are Aminoglycoside antibiotics Anti-coagulants Anti-convulsants Antihypertensives Oral contraceptive Drugs that act on the CNS 14

15 Types of drug interactions Pharmacokinetic interactions Absorption interactions Protein binding displacement interactions Cellular distribution interactions Metabolism interactions Excretion interactions Pharmacodynamic interactions Direct pharmacodynamic interactions Indirect pharmacodynamic interactions 15

16 Pharmacokinetic interactions When the Absorption, Distribution, Metabolism or Excretion of the object drug is altered by the precipitant drug Absorption interactions Reduced gastrointestinal motility Drugs with anti-cholinergic effects ( e.g. antidepressants) Slows the speed of absorption of drugs Usually does not affect the extent of absorption Binding interactions can be avoided if two drugs are taken an hour or two apart Do not take milk, iron preparations or indigestion remedies at the same time of day as this medicine Sometime beneficial Use of activated charcoal in drug-poising 16

17 Pharmacokinetic interactions Protein binding displacement interactions Displacement of one drug by another from its sites of binding to plasma proteins Increased circulation of unbound drug Increased system effect of the displaced drug Object drug must be highly protein bound Important protein-bound object drugs Warfarin Important precipitant drugs involved in protein binding displacement interactions Sulfonamides Cellular distribution interactions E.g. rifampicin inhibits the uptake of certain drugs by hepatocytes Reducing metabolism 17

18 Pharmacokinetic interactions Metabolism interactions Metabolism of object drug is inhibited/increased by a precipitant drug Often involve the cytochrome P 450 system Happens when two drugs are metabolised by the same system Excretion interactions Mostly occur in the kidneys Drugs that inhibit renal tubular excretion increase the blood concentration of object drugs 18

19 Pharmacodynamic Interactions When the precipitant drug alters the effect of the object drug at the site of action Direct pharmacodynamic interactions When two drugs act On the same site Two different sites with similar end result Indirect pharmacodynamic interactions A pharmacological, therapeutic or toxic effect of the precipitant drug alters the pharmacological, therapeutic or toxic effect of the object drug 19

20 A Focus on Common Antiretroviral (ARV) Drug Interactions 20

21 Nucleoside Reverse Transcriptase Inhibitors Drug Interactions

22 Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Zidovudine (AZT/ZDV) Didanosine (ddi) Lamivudine (3TC) Stavudine (d4t) Abacavir (ABC) Emtricitabine (FTC) Nucleotide Reverse Transcriptase Inhibitors Tenofovir Flexner C. Antiretroviral agents and treatment of HIV infection. In: Brunton LL, editor. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12 th edition. The McGraw Hill Companies Inc; 2011

23 Tenofovir Tenofovir DF AMP Kinase Tenofovir TFV-MP Active TFV-DP Diester hydrolysis NDP Kinase Revers e incorporated into HIV DNA to cause chain termination because it has incomplete ribose ring

24 Tenofovir: Pharmacokinetics Tmax Parameter 1.0 ± 0.4 hrs Tenofovir DF Bioavailability 25% Metabolism Tenofovir and Tenofovir DF are not metabolized via CYP450 enzymes Excretion 70 80% as unchanged drug in the urine Half-life 17 hours Effect of food Increase in AUC and Cmax by 35% and 15%

25 Tenofovir Drug Interactions Didanosine is best avoided Lopinavir-ritanovir coadministration needs close monitoring Monitor closely for adverse events Avoid drugs that reduce renal function Avoid drugs that compete for active tubular secretion Aciclovir and Valaciclovir (Herpes simplex 1 and 2; Varicellar-zoster viruses) Gangiclovir and Valganciclovir ( Cytomegalovirus CMV infection)

26 Emtricitabine FTC Deoxycytidine kinase CMP/dCMP Kinase FTC- MP FTC- DP NDP Kinase Active FTC- TP Revers e Incorporated into HIV DNA to cause chain termination Emtricitabine lacks 3 hydroxyl group

27 Emtricitabine: Pharmacokinetics Parameter Emtricitabine Absorption Rapid Tmax 1 2 hours Bioavailability 93% Metabolism Limited metabolism via oxidation and glucuronidation Excretion approximately 86% in the urine and 13% as metabolites Half-life Effect of food 10 hours (intracellular up to 39 hours) No change

28 Emtricitabine Drug Interactions Avoid drugs that reduce renal function Avoid drugs that compete for active tubular secretion Aciclovir and Valaciclovir (Herpes simplex 1 and 2; Varicellar-zoster viruses) Gangiclovir and Valganciclovir ( Cytomegalovirus CMV infection)

29 Lamivudine 3TC Deoxycytidine kinase CMP/dCMP Kinase 3TC- MP 3TC- DP NDP Kinase Active 3TC- TP Revers e Incorporated into HIV DNA to cause chain termination Lamivudine lacks 3 hydroxyl group

30 Lamivudine: Pharmacokinetics Parameter Lamivudine Tmax hours Bioavailability 82% to 87% Metabolism is the minor route of elimination Excretion Renal Excretion 70%, Excreted unchanged in the urine Half-life 3 to 7 hours (intracellular half life is hours) Effect of food No change

31 Lamivudine Drug Interactions The likelihood of interactions is low due to the limited metabolism and plasma protein binding and almost complete renal clearance. Not significantly metabolised by cytochrome P 450 enzymes (such as CYP 3A4, CYP 2C9 or CYP 2D6) Lamuvudine may inhibit the intracellular phosphorylation of zalcitabine when the two medicinal products are used concurrently. Used in peripheral neuropathy History of pancreatitis Administration of trimethoprim, a constituent of co-trimoxazole causes an increase in lamivudine plasma levels. Unless the patient has renal impairment, no dosage adjustment of lamivudne is necessary. Lamivudine has no effect on the pharmacokinetics of co-trimoxazole. The possibility of interactions with other medicines administered concurrently should be considered, particularly when the main route is renal.

32 Zidovudine Zidovudine Thymidylate Kinase ZDV-MP ZDV-DP Active ZDV-TP Thymidine kinase NDP Kinase Revers e Incorporated into HIV DNA to cause chain termination Zidovudine lacks 3 hydroxyl group

33 Zidovudine: Pharmacokinetics Parameter Zidovudine Absorption Well absorbed Tmax 0.5 to 1.5 hours Bioavailability 60-70% Metabolism Liver, extensive with significant firstpass metabolism Excretion Renal: Urinary recovery of oral zidovudine 14%, metabolite 74% Half-life 1 hour (intracellular half life is 3-4 hours) Effect of food Unchanged, may be taken with or without a meal

34 Zidovudine Drug Interactions Ganciclovir Use has caused severe haematological toxicity Radiation therapy Increased risk of bone marrow suppression Probenecid Delayed excretion of Zidovusine Valproate Significantly increases zidovudine levels

35 Abacavir Abacavir Cytosolic enzyme ABC-MP CBV-MP Kinase CBV-DP CBV-TP Adenosine phorphortransferase Kinase Active Rever se incorporated into HIV DNA to cause chain termination because lacks 3 hydroxyl

36 Abacavir: Pharmacokinetics Parameter Absorption Tmax Rapid 0.7 to 2 hours Abacavir Bioavailability >80% Metabolism Extensive. Not a substrate or inhibitor of CYPs Excretion Renal 1%, Feces 16% Half-life hours (intracellular carbovir TP up to 21 hours) Effect of food No significant difference

37 Abacavir Drug Interactions Not significantly metabolised by cytochrome P 450 enzymes (such as CYP 3A4, CYP 2C9 or CYP 2D6) nor do they inhibit or induce this enzyme system Potential for clinically significant interactions is low

38 Non-Nucleoside Reverse Transcriptase Inhibitors Drug Interactions

39 Drugs Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Nevirapine (NVP) Efavirenz (EFV) Delavirdine Etravirine Rilpivirine (RPV)

40 NNRTIs Mechanism of Action Noncompetitive inhibitors of HIV Reverse Transcriptase enzyme Binds to hydrophobic pocket in the p66 subunit Binding site is distant from the active site Induces conformational change that reduces its activity

41 Efavirenz Pharmacokinetics Administration with fatty meals increases bioavailability by 50% Highly protein bound: 99% to albumin Half-life is prolonged in liver disease Metabolised in the liver : cytochrome P450 system Excreted in urine (14-34%) and faeces (16-69%)

42 Efavirenz Drug Interactions Efavirens may either inhibit or induce metabolism of hepatically metabolised drugs Protease Inhibitors Do not give concurrently Midazolam, triazolam, ergot alkaloids, terfenamide Increased plasma levels: avoid Rifampicin Induces metabolism of EFV therefore increase EFV dose Anticonvulsants (Phenytoin, Carbamazepine, Phenobarbitone) Serum levels of both EFV and anticonvulsants reduced Warfarin May require warfarin dose adjustment/ monitor INR regularly Oral contraception Reduced efficacy therefore recommend barrier contraception St John Wart

43 Nevirapine Pharmacokinetics and Drug Reactions Pharmacokinetics Extensively metabolised by the cytochrome P450 system Drug Interactions Rifampicin (use Rifambuten instead) Oral contraception Ketoconazole Should not be given concomitantly

44 Take home message You can t remember all drug to drug interactions Make use of resources available to you South African Medicines Formulary (SAMF) University of Liverpool HIV ichart Work from first principles It is possible to predict potential drug to drug interactions

45 Thank you 45

Continuing Education for Pharmacy Technicians

Continuing Education for Pharmacy Technicians Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected

More information

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical

More information

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS 8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI

More information

Antiretroviral Dosing in Renal Impairment

Antiretroviral Dosing in Renal Impairment Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis

More information

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications. Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically

More information

Simplifying HIV Treatment Now and in the Future

Simplifying HIV Treatment Now and in the Future Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line

More information

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions

More information

Odefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow

Odefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Odefsey Generic name: Emtricitabine, rilpivirine, tenofovir alafenamide (TAF) Pharmacological

More information

104 MMWR December 17, 2004

104 MMWR December 17, 2004 104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir

More information

Descovy. (emtricitabine, tenofovir alafenamide) New Product Slideshow

Descovy. (emtricitabine, tenofovir alafenamide) New Product Slideshow Descovy (emtricitabine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Descovy Generic name: Emtricitabine, tenofovir alafenamide (TAF) Pharmacological class: Nucleoside analog reverse

More information

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /

More information

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core

More information

HIV and AIDS. Shan Nanji

HIV and AIDS. Shan Nanji HIV and AIDS Shan Nanji HIV 2 Description: Enveloped Positive Sense HIV 3 Structural Genes: Cleavage of gp160 leads to formation of ENV: Gp120: attachment to host CD4 T Cell Gp41: GAG (p24) Capsid protein

More information

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none

More information

Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents

Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in

More information

Principles of Antiretroviral Therapy

Principles of Antiretroviral Therapy Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,

More information

HIV - Life cycle. HIV Life Cyle

HIV - Life cycle. HIV Life Cyle Human Immunodeficiency Virus Retrovirus - integrated into host genome ne single-strand RA 7,000 bases HIV1 > HIV2 > HIV0 Pathology Destruction of CD4+ T lymphocytes Loss of immune function pportunistic

More information

What's new in the WHO ART guidelines How did markets react?

What's new in the WHO ART guidelines How did markets react? WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting

More information

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and

More information

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University

More information

Management of NRTI Resistance

Management of NRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington

More information

REVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)

REVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information) Expert peer review on application for addition of fixed dose combination formulations of antiretroviral medications in the EML (Adults) REVIEW No. 2 Abacavir + lamivudine (ABC+ 3TC) Tablet (dispersible):

More information

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner

More information

Comprehensive Guideline Summary

Comprehensive Guideline Summary Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and

More information

TB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.

TB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008. TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor

More information

TB/HIV Co-Infection. Tuberculosis and HIV

TB/HIV Co-Infection. Tuberculosis and HIV TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center

More information

WESTERN CAPE ART GUIDELINES PRESENTATION 2013

WESTERN CAPE ART GUIDELINES PRESENTATION 2013 WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory

More information

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920 0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal

More information

nevirapine, zidovudine and lamivudine

nevirapine, zidovudine and lamivudine nevirapine, zidovudine and lamivudine a fixed dose ART combination for HIV treatment http://www.aidsmap.com/hatip nevirapine. zidovudine and lamivudine (non-fixed dose) 2 Information on starting treatment

More information

Antiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August

Antiviral Agents DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU. 06 August Antiviral Agents Dr. Yunita Sari Pane, MS DEPARTEMEN FARMAKOLOGI & TERAPEUTIK FK USU 06 August 2009 1 VIRUSES Obligate intracellular parasites Consist of a core genome in a protein shell and some are surrounded

More information

HIV Drugs and the HIV Lifecycle

HIV Drugs and the HIV Lifecycle HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's

More information

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start

More information

HIV and contraception the latest recommendations

HIV and contraception the latest recommendations 1 8-11 June 2015, Chiang-Mai HIV and contraception the latest recommendations Mary Lyn Gaffield, Sharon Phillips, Rachel Baggaley, Petrus Steyn, and Marleen Temmerman 2 Medical eligibility criteria for

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

Antiviral Chemotherapy

Antiviral Chemotherapy Viruses are intimate intracellular parasites and their destruction may cause destruction of infected cells. Many virus infections were considered to be self-limited. Most of the damage to cells in virus

More information

nevirapine, stavudine and lamivudine

nevirapine, stavudine and lamivudine nevirapine, stavudine and lamivudine Information on starting treatment with: nevirapine (NVP) + stavudine (d4t) + lamivudine (3TC) Nevirapine, stavudine and lamivudine (non-fixed dose) 2 Lead in dosing

More information

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change

More information

Elements for a Public Summary. Overview of disease epidemiology. Epidemiology of the disease

Elements for a Public Summary. Overview of disease epidemiology. Epidemiology of the disease VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Epidemiology of the disease Cytomegalovirus is found throughout all geographic locations and socioeconomic groups, and infects

More information

Pharmacological considerations on the use of ARVs in pregnancy

Pharmacological considerations on the use of ARVs in pregnancy Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl

More information

Selecting an Initial Antiretroviral Therapy (ART) Regimen

Selecting an Initial Antiretroviral Therapy (ART) Regimen Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,

More information

Efavirenz, stavudine and lamivudine

Efavirenz, stavudine and lamivudine efavirenz, stavudine, lamivudine: 1 efavirenz, stavudine and lamivudine First line ART treatment for HIV infection Efavirenz, stavudine and lamivudine efavirenz, stavudine, lamivudine: 2 Slide 1 Information

More information

A. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention

A. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention DRUG OUTLINE A. Definition B. Epidemiology Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/09/05) C. Classification i. Pharmacokinetic DIs ii. Pharmacodynamic DIs D. Recognition E. Prevention

More information

Pharmacological determinants of long-term treatment success

Pharmacological determinants of long-term treatment success Professor David Back Liverpool, UK Pharmacological determinants of long-term treatment success Pharmacological Issues with Antiretroviral Therapy Intrinsic potency Bioavailability Effect of food and other

More information

Information to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines:

Information to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines: Information to be included with an application for inclusion, change or deletion of a medicine in the WHO Model List of Essential Medicines: 1. Summary statement of the proposal for inclusion, change or

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE: FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen

More information

What are the most promising opportunities for dose optimisation?

What are the most promising opportunities for dose optimisation? What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering

More information

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1

Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1 Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,

More information

Vemlidy. (tenofovir alafenamide) New Product Slideshow

Vemlidy. (tenofovir alafenamide) New Product Slideshow Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength

More information

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if

More information

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za ARV Mode of Action Mode of Action Mode of Action - NRTI Mode of Action - NNRTI Mode of Action - Protease Inhibitors Mode of Action - Integrase inhibitor Mode of Action - Entry Inhibitors Mode of Action

More information

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts 1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion

More information

- They come in all sizes. -- General Structure is similar.

- They come in all sizes. -- General Structure is similar. - They come in all sizes. -- General Structure is similar. Centers for Disease Control (CDC) and Prevention. Influenza Prevention and Control. Influenza. Available at: http://www.cdc.gov/ncidod/diseases/flu/fluinfo.htm.

More information

Selected Issues in HIV Clinical Trials

Selected Issues in HIV Clinical Trials Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic

More information

Industry Data Request

Industry Data Request Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,

More information

Selected Issues in HIV Clinical Trials

Selected Issues in HIV Clinical Trials Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic

More information

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

The ART of Managing Drug-Drug Interactions in Patients with HIV

The ART of Managing Drug-Drug Interactions in Patients with HIV The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe

More information

Management of patients with antiretroviral treatment failure: guidelines comparison

Management of patients with antiretroviral treatment failure: guidelines comparison The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/

More information

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014 Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss

More information

SA HIV Clinicians Society Adult ART guidelines

SA HIV Clinicians Society Adult ART guidelines SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with

More information

HIV medications HIV medication and schedule plan

HIV medications HIV medication and schedule plan Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with

More information

MODERN ART FOR AFRICA

MODERN ART FOR AFRICA MODERN ART FOR AFRICA March 2018 A guide for HIV treatment activists and communities in lowand middle-income countries ART today A pricing agreement was recently announced that will speed up access to

More information

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION

TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman

More information

Somnuek Sungkanuparph, M.D.

Somnuek Sungkanuparph, M.D. HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor

More information

Chapter 49. Antiviral Agents

Chapter 49. Antiviral Agents Chapter 49 Antiviral Agents Antiviral Drugs 1. Characters of Virus Viruses are obligate intracellular parasites their replication depends primarily on synthetic processes of the host cell. 2.Classification

More information

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /

More information

The next generation of ART regimens

The next generation of ART regimens The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state

More information

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)

More information

Contraceptive Research and Development Organization

Contraceptive Research and Development Organization COMMONLY USED ABBREVIATIONS AND ACRONYMS IN MTN PROTOCOLS 3TC ACASI AE AIDS ALT ART ARV AST AUC BMD BV CDC cgmp CFR CI CONRAD Cmax Cmin CORE C-PMPA lamivudine audio computer-assisted self interview adverse

More information

C h a p t e r 5 5 HIV Therapy Where are We Now?

C h a p t e r 5 5 HIV Therapy Where are We Now? C h a p t e r 5 5 HIV Therapy Where are We Now? AK Tripathi Professor of Medicine, Physician & Haemato-Oncologist, King George s Medical College, Lucknow Introduction Human Immunodeficiency Virus type

More information

Risk Management Plan Summary

Risk Management Plan Summary Risk Management Plan Summary EDURANT (rilpivirine) 25 mg film-coated tablet Document Version: 1.0 Document Date: 30.10.2017 Based on EU RMP version 7.0 Marketing authorization holder: Janssen-Cilag AG,

More information

Quick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents

Quick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please

More information

A Genetic Test to Screen for Abacavir Hypersensitivity Reactions

A Genetic Test to Screen for Abacavir Hypersensitivity Reactions The Future of Pharmacogenetics in HIV Clinical Care A Genetic Test to Screen for Abacavir Hypersensitivity Reactions Evan Collins & Misty Bath CANAC/ACIIS 15 th Annual Conference Vancouver, BC April 2007

More information

QUALITATIVE AND QUANTITATIVE COMPOSITION

QUALITATIVE AND QUANTITATIVE COMPOSITION COMBIVIR TABLETS QUALITATIVE AND QUANTITATIVE COMPOSITION COMBIVIR tablets contain 150 mg lamivudine and 300 mg zidovudine and are white to off-white capsule-shaped, scored tablets, engraved with GX FC3

More information

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of

More information

Management of Convulsions in HIV Positive Patients

Management of Convulsions in HIV Positive Patients Management of Convulsions in HIV Positive Patients Dr. Rajendra Prasad Shivaswamy 1, Dr. K A Sudarshan Murthy 2, K H Sahithi 3 1 Assistant Professor, Department of Medicine, JSS Medical College, JSS University,

More information

Updates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013

Updates on Revised Antiretroviral Treatment Guidelines Overview 27 March 2013 Updates on Revised Antiretroviral Treatment Guidelines 2013 Overview 27 March 2013 Introduction of Fixed Dose combination (FDC) FDCs will be available in facilities on 1 April 2013 The FDC ARV that will

More information

Can we make first line ART better?

Can we make first line ART better? Can we make first line ART better? Dr Angela Hartwig 8 th SA AIDS Conference, Durban Skills Building Session 15 June 2017 With thanks to Francois Venter and the people who gave him slides Characteristics

More information

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Structured Treatment Interruption in HIV Positive Patients Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007 Objectives To become re-acquainted with the basics of HAART for HIV infection

More information

Criteria for Oral PrEP

Criteria for Oral PrEP Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates

More information

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents

Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning

More information

Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study

Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen

More information

DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA

DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA METABOLISME dr. Yunita Sari Pane DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA Pharmacokinetic absorption distribution BIOTRANSFORMATION elimination Intravenous Administration Oral

More information

Drug Interactions and ORT

Drug Interactions and ORT Drug Interactions and ORT Victorian Opioid Management ECHO Department of Addiction Medicine St Vincent s Hospital Melbourne 2018 Page 1 Methadone/buprenorphine pharmacology and toxicology will be covered

More information

Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa

Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Antiretroviral treatment outcomes after the introduction of tenofovir in the public-sector in South Africa Alana T Brennan, Kate Shearer, Mhairi Maskew, Prudence Ive, Ian Sanne, Matthew P Fox Health Economics

More information

Module Summary of Clinical Pharmacology

Module Summary of Clinical Pharmacology Module 2.7.2 Summary of Clinical Pharmacology Copyright 2003 the GlaxoSmithKline group of companies. All rights reserved. Unauthorised copying or use of this information is prohibited. 2 TABLE OF CONTENTS

More information

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral

More information

The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease

The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project ARV Dosing in End Stage Renal Disease 1. Jayasekara, D., Aweeka, F. T., Rodriguez, R., Kalayjian, R. C., Humphreys, M. H.,

More information

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects

More information

NOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health

NOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health

More information

NEW ZEALAND DATA SHEET. NEVIRAPINE ALPHAPHARM contains lactose. For the full list of excipients, see section 6.1.

NEW ZEALAND DATA SHEET. NEVIRAPINE ALPHAPHARM contains lactose. For the full list of excipients, see section 6.1. NEW ZEALAND DATA SHEET NEVIRAPINE ALPHAPHARM 1. Product Name NEVIRAPINE ALPHAPHARM 200 mg tablet, uncoated. 2. Qualitative and Quantitative Composition Each tablet contains 200 mg of nevirapine. NEVIRAPINE

More information

Supplementary information

Supplementary information Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect: Darunavir Alvogen 400 mg: Each tablet contains mg sunset yellow FCF (E110).

SUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect: Darunavir Alvogen 400 mg: Each tablet contains mg sunset yellow FCF (E110). SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Darunavir Alvogen 400 mg, filmomhulde tabletten Darunavir Alvogen 800 mg, filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

Clinical skills building - HIV drug resistance

Clinical skills building - HIV drug resistance Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)

More information

number Done by Corrected by Doctor

number Done by Corrected by Doctor number 34 Done by حسام ابو عوض Corrected by Waseem Alhaj Doctor مالك الزحلف Antiviral Chemotherapy (chemotherapy is another way of saying drugs بنحب نتفلسف وهيك.(بس When dealing with viruses we are entering

More information

HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV

HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber

More information

Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors

Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious

More information

Year 2002 Paper two: Questions supplied by Jo 1

Year 2002 Paper two: Questions supplied by Jo 1 Year 2002 Paper two: Questions supplied by Jo 1 Question 9 A 37 year old man with known human immunodeficiency virus (HIV) infection for 10 years presents with severe renal colic for which he has no prior

More information